Перейти к содержанию

Sarepta Therapeutics, Inc. (SRPT) stock: revenue, earnings & dividend

Sarepta Therapeutics, Inc. (SRPT, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener SRPT · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
2.2 bn $
Revenue growth
15.6 %
Revenue growth 5y (p.a.)
32.4 %
Net income
-713.41 m $
Net margin
-32.5 %
Operating margin
-31.8 %
Earnings per share (diluted)
-7.13 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
3.35 bn $
Equity
1.14 bn $
Equity ratio
34.1 %
Return on equity
-62.6 %
Cash
801 m $
Operating cash flow
-205.48 m $
Free cash flow
-307.45 m $
Shares outstanding
107,235,848

History

Revenue by fiscal year

2016 5.42 m $
2017 155 m $
2018 301 m $
2019 381 m $
2020 540 m $
2021 702 m $
2022 933 m $
2023 1.24 bn $
2024 1.9 bn $
2025 2.2 bn $

Net income by fiscal year

2016 -267.27 m $
2017 -50.69 m $
2018 -361.92 m $
2019 -715.08 m $
2020 -554.13 m $
2021 -418.78 m $
2022 -703.49 m $
2023 -535.98 m $
2024 235 m $
2025 -713.41 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.2 bn $-713.41 m $-7.13 $–-205.48 m $
20241.9 bn $235 m $2.34 $–-205.79 m $
20231.24 bn $-535.98 m $-5.80 $–-500.99 m $
2022933 m $-703.49 m $-8.03 $–-325.35 m $
2021702 m $-418.78 m $-5.15 $–-443.17 m $
2020540 m $-554.13 m $-7.11 $–107 m $
2019381 m $-715.08 m $––-456.46 m $
2018301 m $-361.92 m $––-388.66 m $
2017155 m $-50.69 m $––-232 m $
20165.42 m $-267.27 m $––-245.82 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)